RESISTANCE TO CLOPIDOGREL ASSESSED BY VASP PHOSPHORYLATION IS A NEGATIVE PROGNOSTIC FACTOR IN PATIENTS UNDERGOING ELECTIVE PCI FOR STABLE CAD. ANALYSIS FROM LABORATORY SUBSTUDY OF PRAGUE 8 TRIAL
Tématický okruh: Intervenční kardiologie | |||||||||||||||||||||||||||||||||||||||||||||||||
Typ: Ústní sdělení - lékařské , Číslo v programu: 218 | |||||||||||||||||||||||||||||||||||||||||||||||||
Petr R.1, Moťovská Z.2, Marinov I.3, Mocova D.2, Widimský P.2 1 III.interní-kardiologická klinika, 3.lékařská fakulta UK, FNKV, Praha, 2 Fakultní nemocnice Královské Vinohrady, 3 UHKT, Praha | |||||||||||||||||||||||||||||||||||||||||||||||||
Purpose. Resistance to clopidogrel is an unfavourable prognostic factor in patients undergoing PCI for acute coronary syndromes. The aim of this analysis was to assess long-term prognosis of patients who are resistant to clopidogrel and are undergoing elective PCI for stable CAD.
Conclusions. Resistance to clopidogrel assessed by VASP is a significant predictor of long-term prognosis in patients undergoing elective PCI for stable CAD. | |||||||||||||||||||||||||||||||||||||||||||||||||